Acute Respiratory Distress Syndrome - Pipeline Review, H2 2013 - New Market Study Published

From: Fast Market Research, Inc.
Published: Wed Oct 23 2013


Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. Acute Respiratory Distress Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- http://www.fastmr.com/prod/689148_acute_respiratory_distress_syndrome_pipeline.aspx?afid=302

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Acute Respiratory Distress Syndrome.
* A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Medinox, Inc., GlaxoSmithKline plc, Altor BioScience Corporation, Mondobiotech Holding AG, Ikaria Inc., Northern Therapeutics, Inc., Faron Pharmaceuticals, Ltd., Clarassance, Inc.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013
- Acute Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2012
- Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2013
- Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2013
- Respiratory Distress Syndrome - Pipeline Review, H1 2013
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »